NCT00150293
Completed
Phase 3
Pregabalin Open-Label Add-On Trial: An Open-Label, Multicenter Follow-On Study to Determine Long-Term Safety and Efficacy in Patients With Partial Seizures.
ConditionsSeizure Disorder, Partial
DrugsPregabalin
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Seizure Disorder, Partial
- Sponsor
- Pfizer
- Enrollment
- 337
- Locations
- 1
- Primary Endpoint
- Safety Efficacy
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
To determine long-term safety and efficacy of pregabalin in patients with partial seizures.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Must have met the inclusion criteria for preceding double-blind study
- •Have received double-blind study medication and wish to receive open-label pregabalin.
Exclusion Criteria
- •Cannot be pregnant or considering becoming pregnant during the course of the study.
- •Cannot be receiving any concomitant medication that could alter the effectiveness of the pregabalin response or affect seizure frequency.
Outcomes
Primary Outcomes
Safety Efficacy
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial SeizuresSeizure Disorder, PartialNCT00141388Pfizer455
Completed
Phase 3
To Evaluate the Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.Seizure Disorder, PartialNCT00141336Pfizer750
Completed
Phase 3
To Evaluate Long-Term Safety and Efficacy of Pregabalin in Patients With Partial Seizures.Seizure Disorder, PartialNCT00141245Pfizer325
Completed
Phase 2
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.Epilepsy, PartialNCT00141414Pfizer82
Completed
Phase 3
Pregabalin Open-Label Extension Trial in Patients With Partial SeizuresEpilepsies, PartialEpilepsy, Complex PartialNCT00143143Pfizer300